Keystone Symposia

Eldorado Hotel & Spa Floorplan

This meeting took place in 2017

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Antimicrobials and Resistance: Opportunities and Challenges (T4)

Organizer(s) Gautam Dantas and Jennifer A. Leeds
October 29—November 1, 2017
Eldorado Hotel & Spa • Santa Fe, NM USA
Discounted Abstract Deadline: Jun 27, 2017
Abstract Deadline: Jul 27, 2017
Scholarship Deadline: Jun 27, 2017
Discounted Registration Deadline: Aug 29, 2017

Supported by the Directors' Fund

Summary of Meeting:
Antimicrobial-resistant (AMR) infections claim numerous lives around the globe annually. This problem is exacerbated by a steady increase in global antimicrobial use and abuse in the clinic and agriculture, and a dearth of novel antimicrobials making it to market. If these scenarios continue unchecked, AMR will cumulatively cost the global economy around 100 trillion dollars by 2050. This conference focuses on the latest work understanding and combatting AMR, including clinical perspectives on AMR diagnostics and management, translational academic perspectives on design of drug regimens and combinations that suppress AMR, pharma perspectives on recent successes and failures in novel antimicrobial development and clinical trials and basic science perspectives on the ecology and transmission of evolving AMR determinants. While these stakeholders are similarly motivated to identify and develop therapies to treat the exceptional, unmet medical need of worsening AMR, their spheres rarely overlap at scientific conferences, leading to communication barriers between subject matter experts. This conference attempts to address this challenge by engaging diverse global perspectives on these topics, including speakers and attendees from academic research, industrial drug development, and healthcare practice and policy.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time

The meeting will begin on Sunday, October 29 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, November 1 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, November 2 in order to fully experience the meeting.


Arrival and Registration

Eldorado Lounge
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Eldorado Lounge



Eldorado B
Poster Setup

Eldorado B
Poster Viewing

Eldorado B
Welcome and Keynote Address

Eldorado A
* Gautam Dantas, Washington University School of Medicine, USA
Session Chair

Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy, India
Antimicrobial Resistance: Managing a Shared Global Resource

Surveillance and Treatment of Resistant Bacterial Infections in Clinical Practice

Eldorado A
* Gavin Barlow, Hull and East Yorkshire Hospitals NHS Trust and University of York, UK
Session Chair

Michael J. Satlin, Weill Cornell Medicine, USA
Clinical Challenges in Treating Patients with Multidrug-Resistant Bacterial Infections

Coffee Break

Carey-Ann D. Burnham, Washington University School of Medicine, USA
Next-Generation Diagnostics: Translating Rapid Pathogen and Resistance Detection to Optimal Antibiotic Prescription

Calvin Brown, University of California, Los Angeles, USA
Short Talk: Automated Diagnosis of Antimicrobial Resistance Using a Mobile Phone-Based Well-Plate Reader

Jean Patel, Centers for Disease Control and Prevention, USA
Combatting Antibiotic-Resistant Bacteria: CDC's Implementation of the National Action Plan

George A. Cortina, University of Virginia, USA
Short Talk: Predicting Allosteric Mutations that Increase Esbl-Mediated Antibiotic Resistance


Eldorado B
Poster Session 1

Eldorado B
Workshop 1: Novel Therapeutic Strategies

Eldorado A
* Jennifer A. Leeds, Novartis Institutes for BioMedical Research, USA
Session Chair

Elizabeth Culp, Yale University, USA
Activation of a Cryptic Glycopeptide Antibiotic-Related Biosynthetic Gene Cluster

Nagakumar Bharatham, BUGWORKS Research India Private Ltd, India
Discovery of a Novel Class of Anti-Bacterial Agents through an Efflux Mitigation Strategy

Alicia Eve Ballok, Massachusetts General Hospital, USA
Small Molecule Inhibitors of the MvfR Quorum Sensing Pathway Reduce Neutrophil Recruitment and Cytotoxicity of Pseudomonas aeruginosa in Mono and Polymicrobial Lung Infection Models

Sarah L. Keasey, United States Army Medical Research Institute of Infectious Diseases, USA
Drug-Specific Tolerance Mechanisms within the Proteome of the Persistence Phenotype

Liz Sockett, University of Nottingham, UK
Predatory Bacteria: “Living Antibiotics” to Treat Antibiotic-Resistant Gram-Negative Infections

Jade Bojkovic, NGM Biopharmaceuticals, USA
Mining the Human Microbiome for Novel Antimicrobials

Marvin J. Miller, University of Notre Dame, USA
Syntheses and Studies of Novel Monobactams and other beta-Lactams with Activity Against Gram-Negative Bacteria, including Carbapenemase-Producing Acinetobacter baumannii

Coffee Available

Fate and Lessons Learned from Recent Drug Development Programs Focused on Resistant Pathogens or Narrow-Spectrum Agents

Eldorado A
* Richa Chandra, Novartis Pharmaceuticals, USA
Session Chair

Lorraine D. Hernandez, Merck Research Laboratories, USA
Monoclonal Antibody Therapy for the Prevention of Recurrent Clostridium difficile Infections

Christopher B. Ford, Seres Therapeutics, USA
Short Talk: Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile infection (CDI)

Lynn E. Connolly, Achaogen, USA
Late-Stage Drug Development: Lessons Learned from Running Resistant Pathogen Focused Clinical Trials

Paul G. Ambrose, Institute for Clinical Pharmacodynamics, USA
The Future is Combination Antimicrobial Therapy: The Question is a Combination of What?

On Own for Dinner



Eldorado B
Alternative Approaches to Tackling Resistant Infections

Eldorado A
* Matthew Henn, Seres Therapeutics, USA
Session Chair

Helen I. Zgurskaya, University of Oklahoma, USA
Synergistic Interplays between Active Drug Efflux and Low Permeability Barrier of the Outer Membrane in Antibacterial Activities and Inhibition of Multidrug Efflux Pumps

Luis Guachalla, Arsanis Biosciences GmbH, Austria
Short Talk: Antibodies Targeting the Lipopolysaccharide O-antigen as a New Approach to Combat Multidrug Resistant Gram-negative Infections

Konstantin Taganov, Blacksmith Medicines, USA
Short Talk: Activity of Non-Hydroxamate LpxC Inhibitors Against Acinetobacter baumannii

Coffee Break

Scott Hultgren, Washington University School of Medicine, USA
Discovery and Development of Anti-Virulence Therapeutics against UTI Adhesins

Rahul M. Kohli, University of Pennsylvania, USA
Short Talk: Targeting the SOS Response to Combat Antibiotic Resistance

Aileen Rubio, Pew Charitable Trusts, USA
Challenges with Animal Models in Advancing Novel Anti-Infectives

On Own for Lunch

Poster Setup

Eldorado B
Poster Viewing

Eldorado B
Coffee Available

Multidrug Evolutionary Strategies to Invert Resistance Selection

Eldorado A
* Timothy D. Read, Emory University, USA
Session Chair

Pamela Yeh, University of California, Los Angeles, USA
Higher-Order Drug Combinations and Suppressive Interactions

Gavin Barlow, Hull and East Yorkshire Hospitals NHS Trust and University of York, UK
Treating Patients with Infections in the 21st Century - Are Antibiotic Cycling and Novel Combinations a Viable Clinical Option?

Karen Bush, Indiana University, USA
Enzymatic Antimicrobial Resistance and the Search for New Inhibitors

Adam R. Renslo, University of California, San Francisco, USA
Short Talk: Reversible Carbapenemase Inhibitors Bridge the Serine-Metallo Divide

Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Eldorado B
Poster Session 2

Eldorado B



Eldorado B
Ecology and Evolution of AMR Transmission Dynamics Across Habitats

Eldorado A
* Michael S. Gilmore, Harvard Medical School, USA
Session Chair

Gautam Dantas, Washington University School of Medicine, USA
Networks of Exchanging Antibiotic Resistance between Commensal, Environmental and Pathogenic Bacteria

Ilana L. Brito, Cornell University, USA
Horizontal Gene Transfer of Antibiotic Resistance in the Gut Microbiome

Brayon Fremin, Stanford University, USA
Short Talk: Assessment of Protein Synthesis in Response to Antibiotic Treatment in the Human Gut Microbiota

Coffee Break

Gerry D. Wright, McMaster University, Canada
The Resistome and Antimicrobial Discovery

Robert Matthew Cooper, University of California, San Diego, USA
Short Talk: Visualizing and Predicting Horizontal Gene Transfer Enhanced by Neighbor Killing in Biofilms

Kathryn E. Holt, University of Melbourne, Australia
Klebsiella as a Key Trafficker of Antibiotic Resistance Genes

On Own for Lunch

Workshop 2: Novel Strategies for AMR Discovery, Diagnostics and Modeling

Eldorado A
* Jennifer A. Leeds, Novartis Institutes for BioMedical Research, USA
Session Chair

Allison K. Guitor, McMaster University, Canada
In-Solution Targeted Capture of Antibiotic Resistance Genes

Glen P. Carter, University of Melbourne, Australia
The Role of Topical Antibiotics and Biocides in the Emergence of Multidrug-Resistant Staphylococcus aureus

Petra Éva Szili, Biological Research Centre, Hungary
Bacterial Genome Engineering Deciphers the Evolutionary Background of Antibiotic Resistance in Clinical Pathogens

Brett E. Etchebarne, Michigan State University, USA
Evaluation of Nucleic Acid Isothermal Amplification Methods for Human Clinical Microbial Infection and Antibiotic Resistance Gene Detection

Alexei Savchenko, University of Calgary, Canada
Structural and Functional Characterization of the Environmental Antibiotic Resistome Determinants

Margot A. Zevon, Merck, USA
Fractionation of Gram-Negative Bacteria for Direct Measurement of Compounds in Subcellular Compartments

Coffee Available

Tackling AMR - Challenges in Drug Development

Eldorado A
* Holly Soutter, discX, USA
Session Chair

Thomas F. Durand-Reville, Entasis Therapeutics, USA
New Compound Uptake Tools to Confront the Challenges of MDR Gram-Negative Antibiotic Discovery

Folkert Reck, Novartis Institutes for BioMedical Research, USA
LYS228, A Novel Monobactam to Treat Infections Caused by Multidrug-Resistant Enterobacteriaceae

Danica Galonic Fujimori, University of California, San Francisco, USA
Peptidyl Transferase Center Methylation in Antibiotic Resistance

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Eldorado A
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Eldorado B
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Eldorado B



*Session Chair †Invited, not yet responded.

We gratefully acknowledge support for this conference from:

Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

We gratefully acknowledge the generous grant for this conference provided by:

National Institutes of Health

Grant No. 1R13AI134087-01

Funding for this conference was made possible (in part) by 1R13AI134087-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

We gratefully acknowledge additional support for this conference from:

ACS Infectious Diseases
Forge Therapeutics, Inc.
Spero Therapeutics

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:


Entasis Therapeutics

Spero Therapeutics

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: John Monson, Director of Corporate Relations, Email:,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Josh May, Director, Technology and Digital Media, Email:,
Phone:+1 970-262-1179